沙利度胺：光化性痒疹患儿的一种选择。
Thalidomide: An option for the pediatric patient with actinic prurigo.
机构信息
Dermatology Department, Universidad Autónoma de Nuevo León, Hospital Universitario "Dr. José Eleuterio González", Monterrey, México.
出版信息
Pediatr Dermatol. 2020 Mar;37(2):362-365. doi: 10.1111/pde.14086. Epub 2019 Dec 25.
PMID:31875999
Abstract
Actinic prurigo (AP) is an immune-mediated photodermatosis that usually starts in childhood and is predominant among American indigenous and mestizo communities. In adults with AP, thalidomide is the treatment of choice; however, there is little information on its use in pediatric patients. We report the case of a 10-year-old girl with AP treated successfully with thalidomide.
摘要
光化性痒疹（AP）是一种免疫介导的光皮病，通常在儿童期开始，主要发生在美洲原住民和混血社区。对于 AP 成人患者，沙利度胺是首选治疗药物；然而，关于其在儿科患者中的应用信息较少。我们报告了一例成功用沙利度胺治疗的 10 岁 AP 女孩病例。
Zotero 插件